Table 2.

Summary of the AS703569 effects on 11 patient-derived breast cancer xenografts

XenograftHistology and subtypep53 statusaPTEN expressionbRB expressionbMDR1 overexpressioncKi67 expressioncResponse to ACResponse to docetaxelResponse to AS703569TGI, %TGD index
HBCx-4IDC, TNmutHighHighNo8,046Low responderNonresponderNonresponder34 (ns)1.4
HBCx-5IDC, HER2+wt0HighNo1,532ResponderResponderResponder652.2
HBCx-8IDC, TNwt0HighNo1,152ResponderLow responderLow responder331.3
HBCx-10IDC, TNmut00No1,640ResponderNonresponderResponder801.8
HBCx-11IDC, TNmutLowHighNo3,500ResponderLow responderLow responder531.6
HBCx-12AIDC, TNmut0HighNo7,040Not doneNot doneResponder602.5
HBCx-12bIDC, TNmut0HighNo7,040ResponderNonresponderResponder481.3
HBCx-15IDC, TNmut0LowNo5,484ResponderResponderNonresponder01
HBCx-16IDC, TNmutHighHighNo7,055ResponderNonresponderResponder541.8
HBCx-17IDC, TN BRCA2-mutatedmutndndnd3,159ResponderNonresponderLow responder402.1
HBCx-24IDC, TNmutndndnd7,810NonresponderLow responderResponder602.4

Abbreviations: IDC, invasive ductal carcinoma; MDR1, multidrug resistance protein 1; nd, not determined; NS, not significant; RB, retinoblastoma protein; TN, triple-negative.

  • ap53 mutations were determined by FASAY Assay as previously described (16).

  • bRb and PTEN are by Western blotting.

  • cMDR1 and Ki67 gene expression were determined by quantitative RT-PCR.